CEO, previously founded and exited two biotech companies, LumiTech and PetScreen. LumiTech was sold to the Cambrex Corp, in 2000. He is author of six international patents for novel testing methods which now belong to Lonza. PetScreen was a company identifying novel biomarkers associated with acute and chronic veterinary disease also provided resultant novel testing services based on these biomarkers to vets in practice. He is a pioneer of combining multiple biomarker tests using algorithms for the veterinary sector. PetScreen was sold to Avacta Animal Health in 2013. Dr Slater was the Chief Scientific Officer for Avacta until October 2017.